论文部分内容阅读
目的探讨血清AFP、CEA、CA199和CA125联合检测在原发性肝癌诊断中的应用。方法选择48例原发性肝癌患者、50例肝炎肝硬化患者和48例正常对照者血清AFP、CEA、CA199和CA125水平。结果原发性肝癌组血清AFP、CEA、CA199和CA125水平分别为(168.3±48.3)g/L,(12.8±4.9)g/L,(80.5±21.0)kU/L and(111.3±23.9)kU/L均明显高于良性肝病组和正常对照组(P<0.05)。结论 AFP、CEA、CA199和CA125三项联合检测能够明显提高原发性肝癌诊断的敏感性,弥补单项检测的不足。
Objective To explore the application of combined detection of serum AFP, CEA, CA199 and CA125 in the diagnosis of primary liver cancer. Methods Serum levels of AFP, CEA, CA199, and CA125 were determined in 48 patients with primary liver cancer, 50 patients with liver cirrhosis, and 48 normal controls. Results The levels of serum AFP, CEA, CA199 and CA125 in the primary liver cancer group were (168.3±48.3) g/L, (12.8±4.9) g/L, (80.5±21.0) kU/L and (111.3±23.9) kU respectively. /L was significantly higher than benign liver disease group and normal control group (P<0.05). Conclusion The combined detection of AFP, CEA, CA199 and CA125 can significantly improve the sensitivity of diagnosis of primary liver cancer, and make up for the lack of individual detection.